Rexnord Corporation (NYSE:RXN) shares fell to a low of $49.26 before closing at $50.05. Intraday shares traded counted 0.56 million, which was 7.41% higher than its 30-day average trading volume of 608.77K. RXN’s previous close was $49.32 while the outstanding shares total 119.81M. The firm has a beta of 1.45, a 12-month trailing P/E ratio of 36.56, and a growth ratio of 3.10. The stock’s Relative Strength Index (RSI) is 50.95, with weekly volatility at 1.86% and ATR at 1.27. The RXN stock’s 52-week price range has touched low of $27.15 and a $52.78 high. The stock traded higher over the last trading session, gaining 1.48% on 05/26/21.
Investors have identified the Specialty Industrial Machinery company Rexnord Corporation as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $5.88 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Rexnord Corporation (RXN) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For RXN, the company has in raw cash 307.3 million on their books with 2.5 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 1.01 billion total, with 356.3 million as their total liabilities.
RXN were able to record 62.1 million as free cash flow during the 11/02/2021 quarter of the year, this saw their quarterly net cash flow reduce by 51.7 million. In cash movements, the company had a total of 71.3 million as operating cash flow.
Potential earnings growth for Rexnord Corporation (RXN)
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 318.2 million trying to sell their products during the last quarter, with the result yielding a gross income of 207.9 million. This allows shareholders to hold on to 119.81M with the recently reported earning now reading 0.42 cents per share. This is a figure that compared to analyst’s prediction for their 11/02/2021 (0.47 cents a share).
Having a look at the company’s valuation, the company is expected to record 2.30 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on RXN sounds very interesting.
Is the stock of RXN attractive?
In related news, Vice Pres.-General Counsel, Whaley Patricia M sold 2,589 shares of the company’s stock in a transaction that recorded on May 25. The sale was performed at an average price of 50.37, for a total value of 130,395. As the sale deal closes, the Vice Pres.-General Counsel, Whaley Patricia M now sold 33,136 shares of the company’s stock, valued at 1,654,338. Also, VP-Rexnord Business Systems, Chhabra Sudhanshu sold 467 shares of the company’s stock in a deal that was recorded on May 17. The shares were price at an average price of 50.65 per share, with a total market value of 23,656. Following this completion of acquisition, the Group Ex., President-Zurn, Wehr Craig now holds 4,026 shares of the company’s stock, valued at 199,810. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.00%.
5 out of 8 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Rexnord Corporation. 0 analysts has assigned a Sell rating on the RXN stock. The 12-month mean consensus price target for the company’s shares has been set at $57.71.